What's Going On With ACADIA Pharmaceuticals Stock?

ACADIA Pharmaceuticals Inc ACAD shares are trading lower by 4.11% to $15.62 during Tuesday’s session after the company appointed Catherine Owen Adams as CEO.

What Happened: Acadia Pharmaceuticals announced that Catherine Owen Adams has succeeded Steve Davis as CEO and joined the board of directors. Acadia says Catherine brings extensive leadership experience from her roles at Bristol Myers Squibb and Johnson & Johnson, where she oversaw significant growth and product launches.

The board meanwhile expressed confidence in Adams’ ability to drive Acadia’s next phase of growth, emphasizing her strategic vision and commitment to patient outcomes. Steve Davis was also thanked for his leadership, particularly for his role in the approval and commercialization of NUPLAZID and DAYBUE.

Read Also: Trump Vs. Harris: 2024 Election Betting Odds Show Vice President Maintains Lead As Race Nears One-Month Mark

Is ACAD A Good Stock To Buy?

An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like ACADIA Pharmaceuticals‘s page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.

These are known as capital allocation programs. ACADIA Pharmaceuticals does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.

For example, if you're looking to earn an annualized return of 11.7%, you'll need to buy a share of New York Mortgage Trust by the Sep. 30, 2024. Once done, you can expect to receive a nominal payout of $0.2 on Oct. 28, 2024.

Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on ACADIA Pharmaceuticals will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.

According to data from Benzinga Pro, ACAD has a 52-week high of $32.59 and a 52-week low of $14.55.